Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
EBMT 2022
#ASH25 | @jenweiying of @MDAndersonNews shares results of the Phase II SAVE study evaluating the all-oral combination of revumenib, ASTX727, and venetoclax in newly diagnosed, unfit patients with NPM1-m or KMT2A-r AML.
Click here to watch:
🎥
#AMLsm… https://twitter.com/i/web/status/2009188433596502358
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, The University of Texas MD Anderson Cancer Center, Houston, TX, ...
ow.ly
🎥 Karthik Ramasamy of @OUHospitals discusses the initial results from a cohort of the RADAR trial, which is evaluating the efficacy of Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed transplant-eligible patients with double hit ultra-high risk #myeloma:
👉…
RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the ...
twitter.com
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)… https://twitter.com/i/web/status/2008883878761582823
At #ASH25, @tamaciro shared updated results from the Phase II RESTORE trial evaluating elritercept in combination with ruxolitinib in patients with #myelofibrosis and anemia.
Find out more by clicking here:
👉 👈
#MPNsm #TrialUpdate #CTSM #HemOnc
Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the updated results from the Phase II RESTORE...
ow.ly
It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸
Click here to watch: 👉
#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM… https://twitter.com/i/web/status/2008599570398281923
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...
ow.ly
EBMT 2022
#ASH25 | @jenweiying of @MDAndersonNews shares results of the Phase II SAVE study evaluating the all-oral combination of revumenib, ASTX727, and venetoclax in newly diagnosed, unfit patients with NPM1-m or KMT2A-r AML.
Click here to watch:
🎥
#AMLsm… https://twitter.com/i/web/status/2009188433596502358
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, The University of Texas MD Anderson Cancer Center, Houston, TX, ...
ow.ly
🎥 Karthik Ramasamy of @OUHospitals discusses the initial results from a cohort of the RADAR trial, which is evaluating the efficacy of Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed transplant-eligible patients with double hit ultra-high risk #myeloma:
👉…
RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the ...
twitter.com
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)… https://twitter.com/i/web/status/2008883878761582823
At #ASH25, @tamaciro shared updated results from the Phase II RESTORE trial evaluating elritercept in combination with ruxolitinib in patients with #myelofibrosis and anemia.
Find out more by clicking here:
👉 👈
#MPNsm #TrialUpdate #CTSM #HemOnc
Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the updated results from the Phase II RESTORE...
ow.ly
It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸
Click here to watch: 👉
#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM… https://twitter.com/i/web/status/2008599570398281923
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...
ow.ly
